What You Should Know
Axoft has raised an oversubscribed $55M Series A led by C.P. Group Innovation, bringing its total funding to over $60M.The capital will be used to expand global clinical trials, progress U.S. regulatory approval for its implantable Brain-Computer Interfaces (iBCIs), and build a GMP manufacturing facility in Cambridge, MA.Axoft’s iBCIs utilize a proprietary material called Fleuron, which is 10,000x softer than traditional polyimide, significantly reducing tissue scarring and signal attenuation.The company has successfully completed first-in-human clinical trials in 11 patients at sites including Mass General Brigham, The Panama Clinic, and a hospital in China.Fleuron is now commercially available for biomedical applications via an exclusive licensing agreement with Stanford University.
The field of neurotechnology is currently limited by a “material mismatch”: the human brain is soft and dynamic, while most conventional implants are rigid and prone to causing tissue damage. Axoft, a Cambridge-based neurotech pioneer, is solving this fundamental bottleneck with the launch of its bio-inspired iBCI platform. By utilizing a proprietary material that mimics the mechanical properties of brain tissue, Axoft is enabling long-term, high-density neural data capture that was previously impossible with existing hardware.
This breakthrough is underpinned by a $55 million Series A investment that will transition Axoft from a research-focused entity to a global clinical and manufacturing power. The funding allows the company to move aggressively toward U.S. regulatory milestones while simultaneously scaling its international clinical footprint. With neurological disorders affecting one in three people worldwide, the ability to safely decode brain signals at high resolution represents a critical shift in the standard of care for conditions ranging from tumor mapping to disorders of consciousness.
Fleuron: A New Frontier in Biocompatible Hardware
The core differentiator for Axoft is Fleuron, an ISO-10993 compliant material that is significantly more compatible with human biology than the polyimide standard. Fleuron offers 32x more sensors per thread and 8x more region access, while reducing signal loss by over 60%. This allows for “single-cell electrophysiology” at scale, providing the high-fidelity data required to power the next generation of AI-driven brain health models.
The material’s utility extends beyond Axoft’s own implants. Through a licensing agreement with Stanford University, Fleuron is now available to the broader biomedical engineering community for applications in biohybrid devices, organ-on-a-chip technology, and microfluidics. This “platform approach” positions Axoft not just as a device manufacturer, but as a primary infrastructure provider for the entire neurotechnology ecosystem.
Global Clinical Momentum and Infrastructure Scaling
Axoft has already demonstrated the safety and efficacy of its platform through in-human studies involving 11 patients globally. At The Panama Clinic, the company successfully recorded 20 minutes of activity across various cortical and subcortical regions during tumor resections. In the U.S., a collaboration with Mass General Brigham is pushing the boundaries of human cortical mapping and language recognition tasks.
To support this rising demand, Axoft is building a good manufacturing practice (GMP) facility in Cambridge, MA. This facility will enable the mass production of its iBCIs and proprietary materials, ensuring the company can meet the needs of both its clinical partners and its commercial material customers. This move into domestic manufacturing, supported by grant funding from the Massachusetts Manufacturing Innovation Initiative, highlights the company’s commitment to building a sustainable, long-term neurotech hub in New England.